Maintenance Capecitabine and Bevacizumab Versus Bevacizumab Alone After Initial First-Line Bevacizumab and Docetaxel for Patients with Her2-Negative Metastatic Breast Cancer (Imelda): a Randomised, Open-Label, Phase 3 Trial

AuthID
 P-009-YVB
12
Author(s)
Doval, D
·
Bines, J
·
Pierga, JY
·
Costa, R
·
Srock, S
·
Mustacchi, G
Document Type
Article
Year published
2014
Published
in LANCET ONCOLOGY, ISSN: 1470-2045
Volume: 15, Issue: 12, Pages: 1351-1360 (10)
Indexing
Wos®
Scopus®
Crossref®
Google Scholar®
Publication Identifiers
SCOPUS: 2-s2.0-84908229537
Wos: WOS:000344546400046
Source Identifiers
ISSN: 1470-2045
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service